New oral drug aims to tame severe eczema in teens
NCT ID NCT07712536
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests an experimental oral medication called QY201 in adolescents aged 12 to 17 with moderate to severe atopic dermatitis (eczema). Participants take either 10 mg or 20 mg of QY201 twice daily for 28 days. The main goal is to understand how the drug moves through the body and to check its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QY201 tablets (10 mg or 20 mg twice daily)
- What this could lead to
- If successful, this could lead to a new oral treatment option for adolescents with moderate to severe atopic dermatitis.
- What could go wrong
- This is an early phase 2a study with only 24 participants, so results may not generalize. The drug's safety and effectiveness are still unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADOLESCENT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hangzhou First People's Hospital
Hangzhou, Zhejiang, 310000, China